Prof Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany), Prof Karim Fizazi (Institut Gustave Roussy, Villejuif, France), Prof Laura-Maria Krabbe (University of Muenster Medical Center, Muenster, Germany) and Prof Gerhardt Attard (University College London: Cancer Institute, London, UK) discuss PARPi combinations to treat patients with mCRPC.

Prof Merseburger and Prof Attard initially discuss testing for prostate cancer.

The panel discusses the updates from the MAGNITUDE, TALAPRO-2 and PROpel trials. 

They further give an overview of any recent approvals of PARPis.